Jim Cramer's top 10 things to watch in the stock market Monday

Block's shares surged on its impending S&P 500 inclusion, while Verizon reported a Q2 earnings beat and raised its 2025 profit outlook. Analyst sentiment was largely positive, with price target increases for DoorDash, Uber, United Rentals, Caterpillar, Cummins, and Amazon, reflecting confidence in delivery, machinery, and e-commerce sectors, though Target faced a downgrade due to sales concerns. Conversely, Sarepta Therapeutics saw a significant decline after the FDA withdrew support for its gene therapy Elevidys following patient deaths, underscoring regulatory risks. These company-specific and analyst-driven movements unfold amidst a strong start to the Q2 earnings season and anticipation of a new spending bill boosting the broader economy.

Analysis

The market is displaying strong conviction in sector leaders, underscored by a positive start to Q2 earnings season and anticipated fiscal stimulus. In technology, Block's (SQ) shares are rising on a technical catalyst—its upcoming S&P 500 inclusion—while analysts are rewarding demonstrated market dominance. Bernstein significantly raised price targets for DoorDash (to $265) and Uber (to $110), labeling them 'winner-takes-all' in delivery and ride-hailing, respectively. Similarly, Verizon (VZ) posted a Q2 earnings beat at $1.22 per share versus a $1.19 estimate and raised its 2025 adjusted profit growth forecast to 1-3%, signaling solid operational execution. The industrial sector is also showing resilience against recessionary fears, with Barclays lifting price targets for United Rentals, Caterpillar, and Cummins, acknowledging the group's underestimation. Conversely, significant negative catalysts are punishing specific firms. Sarepta Therapeutics (SRPT) stock fell another 8% after a 36% plunge following the FDA's withdrawal of support for its gene therapy, Elevidys, due to three patient deaths. In retail, Target (TGT) was downgraded to 'sell' by Barclays, citing expectations of continued sales underperformance and a lack of competitive edge, creating a clear divergence from preferred names in the space.

Key Decisions for Investors

• Given the FDA's withdrawal of support for Elevidys, investors should treat Sarepta Therapeutics with extreme caution, as the stock faces severe regulatory headwinds and an uncertain path forward for its key therapy.
• The downgrade of Target to 'sell' due to weak sales and a lack of a competitive moat suggests investors should re-evaluate their positions in the retail sector, potentially rotating towards companies with stronger customer loyalty and value propositions.
• Bullish analyst actions on DoorDash and Uber, framing them as 'winner-takes-all' players, alongside Verizon's strong earnings and guidance, indicate that the market is rewarding clear market leaders, warranting a portfolio review to ensure exposure to companies with demonstrated dominance.
• The outperformance and upward price target revisions for industrial machinery stocks challenge prevailing recession forecasts, suggesting it may be prudent to reassess underweight positions in cyclical sectors that are showing fundamental strength.